Monoclonal Antibodies (MAb)

Recent discoveries have revealed much about the nature of PNH, including the role of complement in its pathophysiology. This new knowledge has led to advances in the treatment of PNH, most notably, the use of monoclonal antibodies. Specific proteins that are normally found attached to cells via GPI anchors are absent from the surface of PNH cells. Monoclonal antibody therapy in PNH interrupts the complement cascade and helps preserve PNH cells, thereby significantly reducing chronic hemolysis (as measured by LDH).^1,2

Next: Palliative Therapies for PNH